Thalidomide induces mucosal healing in postoperative Crohn disease endoscopic recurrence

Abstract

Background:Thalidomide has been successful use in patients with refractory Crohn disease (CD) in recent years.Methods:We collected the data of a postoperative CD patient who was prescribed thalidomide to induce remission and reviewed the relevant literatures.Results:A 51-year-old female was diagnosed as CD after an urgent terminal intestinal resection and presented endoscopic recurrence despite the prophylactic treatment with azathioprine (AZA). Fortunately, she achieved mucosal healing (MH) at a low dose of thalidomide for 15 months.Conclusion:Thalidomide is effective to induce MH in the postoperative CD endoscopic recurrence.

Thalidomide Prevented and Ameliorated Pathogenesis of Crohn’s Disease in Mice via Regulation of Inflammatory Response and Fibrosis

“…Therefore, refractory CD is still important problems facing clinicians. Thalidomide has been proved to be effective for the treatment of refractory CD (Hu et al, 2016;Simon et al, 2016;Wang et al, 2017;He et al, 2017;Zhu et al, 2017;Lazzerini et al, 2017). Lazzerini et al analyzed long term results of children treated with thalidomide (administered at a daily dosage of 50 mg, 100 mg, or 150 mg for patents <30 kg, 30-60 kg, and >60 kg), 54.3% maintained clinical remission, 41.4% achieved mucosal healing, and 28.6% achieved histologic healing (Lazzerini et al, 2017).…”

“…In 1965, Sheskin first published a series of studies on the successful treatment of erythema nodules of leprosy with thalidomide, suggesting that thalidomide has anti-inflammatory activity (De las Aguas, 1971). Thalidomide is emerging as an alternative treatment of selected patients with refractory CD and widely used in clinic (Hu et al, 2016;He et al, 2017;Wang et al, 2017;Zhu et al, 2017). Thalidomide could promote endoscopic and histologic healing in children with inflammatory bowel disease and induce clinical remission and mucosal healing in adults with active refractory CD (Simon et al, 2016;Lazzerini et al, 2017).…”

Identification of Four Key Biomarkers and Small Molecule Drugs Innasopharyngeal Carcinoma by Weighted Gene Co-expression Network Analysis

“…Thalidomide, is a glutamic acid derivative, which was a classic drug with immunemodulatory properties and tumor necrosis factor alpha inhibits [50][51][52]. Subsequent studies found that thalidomide has anti-angiogenic, anti-in ammatory, anti-brotic and immune-modulatory effects, and the clinical effectiveness of thalidomide has been con rmed in the treatment of certain disease such as refractory Crohn's disease, lung metastasis, multiple myeloma, hepatocellular carcinoma, and breast carcinoma [53][54][55][56][57][58][59][60]. Our results based on the CMAP database may provide several potential smallmolecule drugs as to future therapy for NPC; nevertheless, studies in vivo and in vitro experiments are necessary.…”

Thalidomide-induced sinus bradycardia in Crohn’s disease: case report and literature review

“…Additionally, clinical remission and mucosal healing were achieved by thalidomide in this patient, which is consistent with findings from previous studies. 11–13,15,16…”

“…[8][9][10][11][12][13][14] Recently, the role of thalidomide in inducing and maintaining mucosal healing in patients with CD has been reported in case series and a prospective open-label study that was performed at our center. [11][12][13]15,16 Moreover, endoscopic and histological healing induced by thalidomide was recently reported in multicenter trials. 17 However, long-term use of thalidomide is limited owing to the high incidence of adverse events, including peripheral neuropathy, somnolence, and constipation.…”